Journal of Cystic Fibrosis (2016)
ASM Microbe 2016 (June 16–20, 2016, Boston, MA)
Annals of Clinical Microbiology and Antimicrobials (2016)
TGV-inhalonix lead product is a nebulized Mul-1867 solution designed for convenient self-administration. Mul-1867 is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi. Initial testing indicates Mul-1867 to be a significant breakthrough in the war on lung infections in patients with cystic fibrosis.
Mul-1867 was Granted Orphan Drug Status from FDA to treat lung infections in CF that addresses unmet medical needs.
Mul-1867 targets biofilm-associated lung infections caused by a number of bacteria and fungi, including P.aeruginosa, S.aureus (including MRSA,VISA/VRSA),B.cepacia, H.influenzae, Aspergillus spp., Candida spp., etc.
TGV-inhalonix recently completed its first-in-human pilot study of Mul-1867 in 15 cystic fibrosis patients with chronic infections (outside the US). With an inhaled delivery directly to the sites of pulmonary infection, Mul-1867 was shown to be clinically safe and effective.
Highlights of Mul-1867 –Three “Effective against”:
- Effective against resistant microorganisms
- Effective against biofilms
- Effective against mixed bacterial-bacterial and bacterial-fungal infections